Manufacturers report positive results from two phase 3 adult studies evaluating investigational 15-valent pneumococcal conjugate vaccine

In the PNEU-PATH and PNEU-DAY studies the 15-valent pneumococcal conjugate vaccine (including serotypes 22F and 33F) delivered immune responses comparable to PCV13 for the 13 shared serotypes and higher immune responses for serotypes 22F and 33F at 30 days.

Source:

Biospace Inc.